Welcome : Guest

Rising Incidence of Fibromyalgia Syndrome and Anticipated Launch of New Drugs to Spur Growth in the Fibromyalgia Therapeutics Market


Published: April 2017

REPORT STATISTICS


  • Code: MCP-6917
  • Pages: 78
  • Tables: 8
  • Companies: 22


FIBROMYALGIA THERAPEUTICS: A RESEARCH BRIEF

The global market for Fibromyalgia Therapeutics is projected to reach US$1.8 billion by 2022, driven by the rise in incidence and diagnosis of fibromyalgia syndrome and the expected launch of new drugs that are currently in research stage. Growing awareness among the medical community and the expected decline in widespread misdiagnosis and misunderstanding of the disease is forecast to benefit growth in the market in the coming years. Improving diagnostic criteria supported by continuous R&D efforts; and launch of newer, and more potent premium higher priced therapies are expected to accelerate value growth of the market. The United States represents the largest and the fastest growing market worldwide supported by incidence rates as high as 3-5% of the total population; growing awareness and overall understanding of the disease as a result of high profile awareness campaigns. The country's dominance in the global market is also due to the fact that it is the only country to have approved three fibromyalgia drugs namely Cymbalta, Lyrica and Savella. 

    Summary of Findings

  • Off-Label Use of Analgesics, Sedatives, Muscle Relaxants, Neuroleptics and Anti-Depressants in the Treatment of Fibromyalgia Witnesses Strong Growth Supported by Huge Unmet Treatment Needs
  • Rise of Fibromyalgia as a “Real” Health Condition and Active Research in Brain Based Diagnosis of the Disease to Benefit Market Growth
  • Development of Alternative Fibromyalgia Treatment Procedures such as High-Pressure Oxygen Application to Bring-In Unconventional Growth in the Market
  • Approval of Transcranial Direct Current Stimulation Procedure to Treat Fibromyalgia in Europe to Benefit Global Market Growth
  • Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine

    Timeline for Analysis

  • Market Estimates and Forecasts for 2015-2022
  • Historic Review 2009-2014

    Geographic Markets Analyzed

  • US, Japan, Europe (France, Germany, Italy, UK, Spain and Rest of Europe), and Rest of World

MAJOR PLAYERS

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts, Inc.
  • Pfizer, Inc.
  • Pierre Fabre Médicament
  • SWITCHBIOTECH LLC

KEY RESEARCH DELIVERABLES

  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable

INFOGRAPHICS ON FIBROMYALGIA THERAPEUTICS

1. http://www.mba-healthcare-management.com/fibromyalgia/